HC Wainwright Issues Negative Estimate for AMLX Earnings

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Investment analysts at HC Wainwright dropped their Q3 2026 EPS estimates for Amylyx Pharmaceuticals in a report released on Friday, August 7th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.35) per share for the quarter, down from their prior estimate of ($0.33). HC Wainwright currently has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.49) EPS, FY2027 earnings at ($1.40) EPS and FY2028 earnings at ($1.08) EPS.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03).

A number of other research analysts have also weighed in on AMLX. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Mizuho increased their price target on Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the company an “outperform” rating in a research note on Monday, July 20th. Wall Street Zen cut Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Citigroup lifted their price objective on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Guggenheim upped their price objective on Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Amylyx Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $25.38.

Amylyx Pharmaceuticals Stock Down 0.7%

Shares of AMLX stock opened at $22.67 on Tuesday. The company’s fifty day simple moving average is $17.54 and its two-hundred day simple moving average is $15.81. Amylyx Pharmaceuticals has a 52 week low of $7.61 and a 52 week high of $24.60. The stock has a market cap of $2.53 billion, a P/E ratio of -15.85 and a beta of -0.21.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of AMLX. Landscape Capital Management L.L.C. increased its position in shares of Amylyx Pharmaceuticals by 17.5% during the 4th quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company’s stock valued at $148,000 after purchasing an additional 1,825 shares during the last quarter. KBC Group NV purchased a new stake in Amylyx Pharmaceuticals during the 1st quarter valued at $26,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Amylyx Pharmaceuticals by 54.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock worth $64,000 after buying an additional 1,890 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in Amylyx Pharmaceuticals in the fourth quarter worth $25,000. Finally, State of Wyoming purchased a new position in Amylyx Pharmaceuticals during the second quarter worth $40,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Insider Buying and Selling

In related news, insider Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the completion of the transaction, the insider owned 194,090 shares in the company, valued at approximately $3,555,728.80. This trade represents a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 10.90% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.